Compare Stocks → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CALANASDAQ:ELDNNASDAQ:MBRXNASDAQ:ONTXOTCMKTS:VICP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.02$0.02$0.01▼$0.50$97KN/A799 shs57 shsELDNEledon Pharmaceuticals$2.41+4.8%$1.86$1.07▼$2.95$59.79M0.86137,174 shs178,489 shsMBRXMoleculin Biotech$5.02-2.5%$6.43$4.28▼$15.75$11.20M1.8523,850 shs16,521 shsONTXOnconova Therapeutics$0.85$0.55▼$1.45$20.90M1.3896,681 shs1.28 million shsVICPVicapsys Life Sciences$0.99$1.52$0.54▼$3.00$31.75M-5.6373 shsN/ABeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences0.00%0.00%0.00%-36.00%-20.00%ELDNEledon Pharmaceuticals+4.78%+16.99%+42.60%+39.31%+1.69%MBRXMoleculin Biotech-2.14%+5.24%-4.38%-33.95%-56.25%ONTXOnconova Therapeutics0.00%0.00%0.00%+38.81%-28.40%VICPVicapsys Life Sciences0.00%+1.02%+2.06%-50.26%-1.01%Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALACalithera BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AELDNEledon Pharmaceuticals3.5189 of 5 stars3.55.00.00.02.91.71.3MBRXMoleculin Biotech2.1011 of 5 stars3.55.00.00.00.00.01.3ONTXOnconova Therapeutics0.7192 of 5 stars3.53.00.00.00.00.00.0VICPVicapsys Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALACalithera BiosciencesN/AN/AN/AN/AELDNEledon Pharmaceuticals3.00Buy$10.67342.60% UpsideMBRXMoleculin Biotech3.00Buy$35.00597.21% UpsideONTXOnconova Therapeutics3.00Buy$11.00∞ UpsideVICPVicapsys Life SciencesN/AN/AN/AN/ACurrent Analyst RatingsLatest CALA, MBRX, ONTX, ELDN, and VICP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024MBRXMoleculin BiotechRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.003/26/2024MBRXMoleculin BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $20.003/22/2024ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALACalithera Biosciences$9.75M0.01N/AN/A($0.40) per share-0.05ELDNEledon PharmaceuticalsN/AN/AN/AN/A$3.45 per shareN/AMBRXMoleculin BiotechN/AN/AN/AN/A$11.70 per shareN/AONTXOnconova Therapeutics$230K0.00N/AN/A$1.35 per share0.00VICPVicapsys Life SciencesN/AN/AN/AN/A($0.03) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALACalithera Biosciences-$39.65MN/A0.00∞N/AN/AN/AN/AN/AELDNEledon Pharmaceuticals-$40.33M-$1.79N/AN/AN/AN/A-46.15%-43.10%5/9/2024 (Estimated)MBRXMoleculin Biotech-$29.77M-$13.64N/AN/AN/AN/A-80.91%-67.69%5/9/2024 (Estimated)ONTXOnconova Therapeutics-$18.96M-$0.91N/AN/AN/A-8,930.97%-95.43%-61.19%5/20/2024 (Estimated)VICPVicapsys Life Sciences-$990KN/A0.00∞N/AN/AN/A-598.80%N/ALatest CALA, MBRX, ONTX, ELDN, and VICP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023ELDNEledon Pharmaceuticals-$0.38-$0.29+$0.09-$0.29N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALACalithera BiosciencesN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/AONTXOnconova TherapeuticsN/AN/AN/AN/AN/AVICPVicapsys Life SciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALACalithera BiosciencesN/AN/AN/AELDNEledon PharmaceuticalsN/A14.4114.41MBRXMoleculin BiotechN/A3.863.86ONTXOnconova TherapeuticsN/A2.792.79VICPVicapsys Life SciencesN/A0.130.13OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALACalithera BiosciencesN/AELDNEledon Pharmaceuticals56.77%MBRXMoleculin Biotech15.52%ONTXOnconova Therapeutics7.95%VICPVicapsys Life SciencesN/AInsider OwnershipCompanyInsider OwnershipCALACalithera Biosciences6.60%ELDNEledon Pharmaceuticals19.40%MBRXMoleculin Biotech6.70%ONTXOnconova Therapeutics3.30%VICPVicapsys Life Sciences5.98%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCALACalithera Biosciences84.87 million4.55 millionNot OptionableELDNEledon Pharmaceuticals2024.81 million20.00 millionOptionableMBRXMoleculin Biotech182.23 million2.08 millionNot OptionableONTXOnconova Therapeutics1621.00 million20.31 millionOptionableVICPVicapsys Life Sciences232.07 million30.15 millionNot OptionableCALA, MBRX, ONTX, ELDN, and VICP HeadlinesSourceHeadlineBest term life insurance: Expert-rated in April 2024usatoday.com - April 28 at 1:24 AMScanning Electron Microscopy for the Life Sciencescambridge.org - April 20 at 9:36 AMEY Life Sciencespmlive.com - April 8 at 1:51 PMLife Sciencedmagazine.com - January 30 at 8:57 AMCaris Life Sciencesdmagazine.com - November 30 at 3:41 PMAnavex Life Sciences Corp AVXLmorningstar.com - November 4 at 11:28 PMVICP - Vicapsys Life Sciences, Inc.finance.yahoo.com - August 9 at 4:25 PMViCapsys files for Nasdaq uplisting, $8M public offeringmsn.com - July 3 at 3:00 PMLife sciences sector to get £650m boost in new Government funding packageaol.co.uk - June 9 at 8:18 PM‘Not Seeing Any Activity At All’: Once-Hot Life Sciences Leasing Market Freezesbisnow.com - April 1 at 1:05 PMThe Science of Lifenature.com - March 29 at 10:46 AMThe ultimate list of leaders in life sciences.statnews.com - March 16 at 7:27 AMDefining life and personhood: What science, philosophy, and religion have to saykcrw.com - March 13 at 10:54 AMLife Sciences Innovator Category Winner 2023news-medical.net - February 23 at 7:19 AMGlobal law firm Goodwin is setting up a Philly tech, startups and life sciences practicetechnical.ly - February 21 at 12:23 AMGlobal Life Science Tools Strategic Business Report 2023: Rapid Growth in Biopharma Industry and Rising Investments in R&D to Boost Market Prospectsbenzinga.com - February 19 at 11:43 PMFocused exclusively on life sciences, three top investors set out on their ownstatnews.com - January 28 at 2:12 AMTop risks for life sciences sector revealed – reportcanadianlawyermag.com - January 15 at 1:36 PMHouston On Track As Future Life Sciences Powerhouse, But Everyone Needs To Mind The Gaps Firstbisnow.com - January 15 at 1:36 PM$1.6B Life Sciences Hub Backed By Hochul, Adams Coming To Kips Baybisnow.com - October 16 at 10:15 PMViCapsys Life Sciences Appoints Three New Board Membersfinance.yahoo.com - September 29 at 6:41 PMViCapsys Life Sciences Appoints Federico Pier as Permanent Chief Executive Officerfinance.yahoo.com - April 18 at 12:29 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCalithera BiosciencesNASDAQ:CALACalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Eledon PharmaceuticalsNASDAQ:ELDNEledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Moleculin BiotechNASDAQ:MBRXMoleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.Onconova TherapeuticsNASDAQ:ONTXOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.Vicapsys Life SciencesOTCMKTS:VICPVicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.